Stryker Co. (NYSE:SYK) VP Katherine Ann Owen sold 2,651 shares of the stock in a transaction on Wednesday, April 18th. The stock was sold at an average price of $165.00, for a total value of $437,415.00. Following the completion of the sale, the vice president now owns 7,729 shares in the company, valued at approximately $1,275,285. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Katherine Ann Owen also recently made the following trade(s):
- On Monday, March 26th, Katherine Ann Owen sold 103 shares of Stryker stock. The stock was sold at an average price of $160.00, for a total value of $16,480.00.
- On Monday, March 5th, Katherine Ann Owen sold 3,700 shares of Stryker stock. The stock was sold at an average price of $161.66, for a total value of $598,142.00.
NYSE SYK traded up $0.80 during trading hours on Friday, reaching $164.35. 235,719 shares of the stock traded hands, compared to its average volume of 1,275,703. Stryker Co. has a 1 year low of $131.67 and a 1 year high of $170.00. The company has a quick ratio of 1.59, a current ratio of 2.29 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $61,707.29, a price-to-earnings ratio of 25.12, a PEG ratio of 2.37 and a beta of 0.70.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, April 30th. Stockholders of record on Thursday, March 29th will be paid a dividend of $0.47 per share. The ex-dividend date of this dividend is Wednesday, March 28th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 1.14%. Stryker’s dividend payout ratio (DPR) is currently 28.97%.
Several large investors have recently made changes to their positions in the company. Chemical Bank grew its stake in shares of Stryker by 24.1% during the fourth quarter. Chemical Bank now owns 12,936 shares of the medical technology company’s stock valued at $2,003,000 after buying an additional 2,515 shares during the last quarter. Green Square Capital LLC grew its stake in shares of Stryker by 148.5% during the fourth quarter. Green Square Capital LLC now owns 5,606 shares of the medical technology company’s stock valued at $871,000 after buying an additional 3,350 shares during the last quarter. Rehmann Capital Advisory Group grew its stake in shares of Stryker by 7.8% during the fourth quarter. Rehmann Capital Advisory Group now owns 5,306 shares of the medical technology company’s stock valued at $822,000 after buying an additional 385 shares during the last quarter. Colonial Trust Advisors grew its stake in shares of Stryker by 40.9% during the fourth quarter. Colonial Trust Advisors now owns 33,883 shares of the medical technology company’s stock valued at $5,246,000 after buying an additional 9,836 shares during the last quarter. Finally, Xact Kapitalforvaltning AB grew its stake in shares of Stryker by 7.3% during the fourth quarter. Xact Kapitalforvaltning AB now owns 57,539 shares of the medical technology company’s stock valued at $8,909,000 after buying an additional 3,912 shares during the last quarter. 75.66% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities research analysts recently issued reports on the company. Zacks Investment Research upgraded Stryker from a “sell” rating to a “hold” rating and set a $177.00 price objective on the stock in a research report on Thursday, April 12th. Needham & Company LLC reiterated a “hold” rating on shares of Stryker in a research report on Wednesday, January 17th. Royal Bank of Canada reiterated a “buy” rating and issued a $175.00 price objective on shares of Stryker in a research report on Tuesday, January 9th. ValuEngine upgraded Stryker from a “hold” rating to a “buy” rating in a research report on Thursday, March 1st. Finally, Morgan Stanley increased their price objective on Stryker from $179.00 to $186.00 and gave the stock an “overweight” rating in a research report on Monday, February 26th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and sixteen have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $165.27.
ILLEGAL ACTIVITY NOTICE: This news story was originally published by Week Herald and is the property of of Week Herald. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://weekherald.com/2018/04/20/stryker-co-syk-vp-katherine-ann-owen-sells-2651-shares.html.
Stryker Company Profile
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.